Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
China Resources Pharmaceutical Group Ltd. has arranged for its subsidiary CR Sanjiu Chenzhou to continue sourcing energy for heating and cooling, steam and electricity from CR Gas Chenzhou, an indirect wholly owned subsidiary of China Resources Gas, to support its Southern China manufacturing centre from 1 January 2026 to 31 December 2028 under a new framework agreement. Because both CR Pharmaceutical and CR Gas share a common controlling shareholder, the renewed energy purchase arrangement is classified as a continuing connected transaction under Hong Kong listing rules, triggering reporting, announcement and annual review requirements but exempting it from independent shareholders’ approval, thereby formalising a key utility supply relationship while keeping compliance obligations relatively light.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a Hong Kong-incorporated pharmaceutical company whose operations include manufacturing activities in Southern China, where it runs a major production centre under subsidiary CR Sanjiu Chenzhou.
Average Trading Volume: 13,593,600
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.71B
See more data about 3320 stock on TipRanks’ Stock Analysis page.